Highmark, Inc., entered an outcomes-based agreement with AstraZeneca for Fasenra, an add-on injected prescription maintenance treatment for people age 12 and older with severe asthma. The agreement applies to Highmark’s commercial and Medicare members; about 500 Highmark members currently use Fasenra. For this agreement, Highmark is measuring medication adherence, and improvements in member health.
Highmark has previously entered into value-based contracts for pharmaceutical and biological treatments for several other chronic, high-cost health conditions, including diabetes, autoimmune diseases, asthma, and chronic obstructive pulmonary (COPD). It had previously entered an outcomes-based agreement with AstraZeneca for Symbicort, a medication to treat asthma and COPD. In 2019, Highmark announced that its contract with AstraZeneca for Symbicort demonstrated positive results in improving health outcomes, including through the majority of members on the medication experiencing a stabilization or improvement of their symptoms.
Highmark Inc, is an independent licensee of the Blue Cross Blue Shield (BCBS) Association. It is the fourth largest overall BCBS-affiliated organization, and insures more than 5.6 million members in Pennsylvania, Delaware, and West Virginia
This was reported by Highmark Inc. on September 21, 2020.
Contact information: Sarah Marchè, Senior Vice President, Pharmacy Services, Highmark, Inc., Fifth Avenue Place, 120 Fifth Avenue, Pittsburgh, PA 15222-3099; 412-544-7000; https://www.highmark.com/contact/